GlobeNewswire·Nov 25, 2025, 4:05 PM ET

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting

CG Oncology, Inc. will present late-breaking podium results from BOND-003 Cohort P & first results from CORE-008 Cohort A at the Society of Urologic Oncology (SUO) 26th Annual Meeting in Phoenix, AZ.
The SUO meeting takes place December 2–5, 2025, at the Sheraton Phoenix Downtown.
Two late-breaking podium presentations are scheduled for December 5, 2025, including data on high-risk BCG-unresponsive papillary-only disease & high-risk BCG-naïve carcinoma in situ.
Three additional posters covering 24-month BOND-003 Cohort C outcomes, CORE-008 Cohort B evaluation, & an expanded access program design will be presented December 3–4, 2025.
Cretostimogene Grenadenorepvec is an investigational oncolytic immunotherapy studied in over 400 patients across Phase 3 (BOND-003, PIVOT-006) & Phase 2 (CORE-008) trials.
An Expanded Access Program for BCG-unresponsive patients has been initiated in North America, though FDA approval for safety & efficacy has not yet been established.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing bladder-sparing therapies for non-muscle invasive bladder cancer (NMIBC).